// App-Quantinova.ai

311 : A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.

Researchers

Presenter

  • Jianqing Lin

Principal Investigators

  • Ashwin Reddy Sama

  • Jean H. Hoffman-Censits

  • Brooke Kennedy

  • Deborah Kilpatrick

  • Zhong Ye

  • Hushan Yang

  • Zhaomei Mu

  • Benjamin E Leiby

  • Nancy Lewis

  • Massimo Cristofanilli

  • William Kevin Kelly

Medical Centers

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Thomas Jefferson University, Philadelphia, PA

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • Kimmel Cancer Center Jefferson, Philadelphia, PA

  • Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA

  • Thomas Jefferson University, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Neuroendocrine tumors

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • CB-7598

  • Prednisone

  • Alisertib

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT01848067

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved